Contraception for Women with Polycystic Ovary Syndrome: Dealing with a Complex Condition

This document discussed the complexities of managing contraception for women with Polycystic Ovary Syndrome (PCOS), a condition affecting 9-13% of women of reproductive age. PCOS is associated with menstrual irregularities, hyperandrogenism, and increased cardiometabolic risks. Combined oral contraceptives (COCs) were recommended as the first-line treatment for managing menstrual irregularities and hyperandrogenism in PCOS, offering endometrial protection and reducing androgen levels. However, the choice of contraceptive should be individualized based on the patient's clinical, hormonal, and metabolic profile. Alternatives like progestin-only contraceptives and long-acting reversible contraceptives (LARC) were suggested for those with contraindications to COCs. The document emphasized the importance of considering lifestyle changes and additional treatments for comorbidities in managing PCOS.